CMS model targets Medicaid access to gene therapies for sickle cell disease

Partnering on Population Health. A Black female patient in a hospital bed smiles at a female clinician of color with a smile on her face who is examining the patient in a hospital room.

The Cell and Gene Therapy Access Model, which seeks to increase access to treatments for Medicaid enrollees with rare and severe diseases, will initially focus on sickle cell disease, the Centers for Medicare & Medicaid Services announced. The genetic blood disorder affects over 100,000 Americans, most of whom are Black and at least half of whom are enrolled in Medicaid. The model will begin in 2025.

“Gene therapies for sickle cell disease have the potential to treat this devastating condition and transform people’s lives, offering them a chance to live healthier and potentially avoid associated health issues,” said CMS Administrator Chiquita Brooks-LaSure. “Increasing access to these promising therapies will not only help keep people healthy, but it can also lead to savings for states and taxpayers as the long-term costs of treating sickle cell disease may be avoided.”

Disease Management